STAAR Surgical (NASDAQ:STAA) Receives $25.29 Average PT from Analysts

STAAR Surgical (NASDAQ:STAA) has received an average recommendation of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $25.29.

Several equities analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Jefferies Financial Group lowered STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Stephens reissued an “equal weight” rating and issued a $17.00 price target on shares of STAAR Surgical in a research report on Tuesday, March 18th. Finally, Canaccord Genuity Group cut their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th.

Insider Buying and Selling at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 8,221 shares of the stock in a transaction on Thursday, January 16th. The shares were acquired at an average price of $21.50 per share, with a total value of $176,751.50. Following the completion of the transaction, the insider now owns 10,878,007 shares in the company, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders acquired 1,036,187 shares of company stock worth $17,239,548 in the last quarter. 1.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On STAAR Surgical

Several large investors have recently modified their holdings of the stock. Victory Capital Management Inc. lifted its stake in STAAR Surgical by 16.7% in the third quarter. Victory Capital Management Inc. now owns 189,481 shares of the medical instruments supplier’s stock valued at $7,039,000 after purchasing an additional 27,143 shares during the last quarter. Quest Partners LLC purchased a new position in shares of STAAR Surgical during the 3rd quarter valued at $128,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of STAAR Surgical by 323.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,014 shares of the medical instruments supplier’s stock valued at $1,115,000 after buying an additional 22,925 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of STAAR Surgical during the 3rd quarter worth $463,000. Finally, Larson Financial Group LLC increased its holdings in STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock worth $181,000 after acquiring an additional 2,135 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Trading Up 0.3 %

STAA opened at $17.77 on Friday. The company has a market cap of $876.51 million, a price-to-earnings ratio of -43.34 and a beta of 0.66. The company’s fifty day moving average price is $19.77 and its two-hundred day moving average price is $25.52. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.